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Background. Retinitis pigmentosa (RP) is a blinding genetic disorder that is caused by the death of photoreceptors in the
outer nuclear layer of the retina. To date, 39 different genetic loci have been associated with the disease, and 28 mutated
genes have been identified. Despite the complexity of the underlying genetic basis for RP, the final common pathway is
photoreceptor cell death via apoptosis. Methodology/Principal Findings. In this study, P23H and S334ter rhodopsin
transgenic rat models of RP were used to test the neuroprotective effects of anti-apoptotic gene therapy. Adeno-associated
viruses (AAV) carrying the X-linked inhibitor of apoptosis (XIAP) or green fluorescent protein (GFP) were delivered subretinally
into the eye of transgenic rat pups. Histological and functional measures were used to assess neuroprotection. XIAP is known
to block apoptosis by inhibiting the action of caspases-3, -7 and -9. The results show that XIAP gene therapy provides long-
term neuroprotection of photoreceptors at both structural and functional levels. Conclusions/Significance. Our gene
therapy strategy targets the apoptotic cascade, which is the final common pathway in all forms of retinitis pigmentosa. This
strategy holds great promise for the treatment of RP, as it allows for the broad protection of photoreceptors, regardless of the
initial disease causing mutation.
Citation: Leonard KC, Petrin D, Coupland SG, Baker AN, Leonard BC, et al (2007) XIAP Protection of Photoreceptors in Animal Models of Retinitis
Pigmentosa. PLoS ONE 2(3): e314. doi:10.1371/journal.pone.0000314
INTRODUCTION
Retinitis pigmentosa (RP) is a genetically heterogeneous group of
retinal degenerations and the most common cause of inherited
blindness in the developed world, with an estimated incidence
between 1 in 3000 to 1 in 5000 [1]. The disease is caused by the
degeneration of the photoreceptor cells, with rod photoreceptor
death preceding the secondary loss of cones. RP is characterized
by progressive night blindness, reduction or loss of visual acuity
and constriction and gradual loss of the visual field [2,3]. To date,
39 different genetic loci have been associated with the disease, and
28 mutated genes have been identified [4]. Within these 39 genes,
there are many individual mutations that cause RP. Rhodopsin
mutations are the most prevalent, with over 100 identified. Despite
the complexity of the underlying genetic basis for RP and other
similar retinal degenerative diseases, the final common pathway is
photoreceptor cell death via apoptosis [5–8].
There are a variety of well established rodent models of RP,
based on both spontaneous and engineered genetic mutations. For
the current study, the P23H and S334ter rhodopsin transgenic rat
models were used. The P23H rat has a histidine substituted for
proline in position 23 of the rhodopsin gene [9]. The same
mutation is causative in the most prevalent form of autosomal
dominant retinitis pigmentosa (adRP) in North America, being
linked to approximately 12% of human cases [10]. In the S334ter
rats, the rhodopsin gene has a termination codon at residue 334
which results in the expression of rhodopsin proteins which lack
the 15 C-terminal amino acids [11]. The C-terminus is involved in
rhodopsin trafficking to the photoreceptor outer segments [12] and
in the deactivation of the rhodopsin protein after light absorption
(reviewed in [13]), both of which are key events in phototransduc-
tion. In both rat models, there is a gradual apoptotic loss of
photoreceptors in the outer nuclear layer (ONL) of the retina.
The loss of photoreceptors in RP has been shown to occur via
apoptosis [7]. Apoptotic pathways most often involve a family of
cysteine proteases known as caspases [14], that cleave key cellular
targets, ultimately leading to the death of the cell. A family of
proteins known as the inhibitors of apoptosis (IAPs) block cell death
by interfering with the activity of key caspases. The IAP proteins
contain one or more 70–80 amino acid baculoviral IAP repeat (BIR)
domains, which have a conserved cysteine and histidine core
sequence(Cx2Cx6Wx3Dx5Hx6C).TheBIR domainsandtheirlinker
regions bind to and suppress caspase activity [15,16].
IAPs have been shown to block cellular apoptosis induced by
a wide variety of triggers [17,18]. The X-linked inhibitor of
apoptosis (XIAP) protein is the best characterized and most potent
IAP family member [19]. XIAP contains three BIR domains
which, in conjunction with their linker regions, bind to and inhibit
caspases 3, 7, and 9 [17]. Additionally, XIAP contains a carboxy
terminal RING zinc finger domain that possesses E3 ubiquitin
ligase activity. This domain allows XIAP to auto-ubiquitinate and
self-degrade under severe apoptotic stress [20,21] but can also
promote the ubiquitination and degradation of caspases [22] and
thus suppress apoptosis in conditions of lower apoptotic stress [23].
Gene therapy strategies employing virally-delivered XIAP have
been shown to confer resistance to apoptosis in a variety of in vivo
cell death models. XIAP promotes neuroprotection in forebrain
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PLoS ONE | www.plosone.org 1 March 2007 | Issue 3 | e314[24] and retinal [25] ischemia, in the MPTP model of Parkinson’s
Disease [26,27], in retinal ganglion cell death induced by axotomy
of the optic nerve [28,29] or increased intraocular pressure [30],
and in cisplatin induced ototoxicity [31]. In addition, we have
previously shown that XIAP over-expression can protect photo-
receptors both structurally and functionally in a chemotoxic
animal model of retinal degeneration [32,33]. However, all of
these previous reports of XIAP protection involve acute models of
apoptotic stress. The important question remains whether XIAP
gene therapy can be efficacious in models of chronic stress caused
by genetic mutation.
The present study examines the neuroprotective effects of XIAP
gene therapy in genetic models of RP. We hypothesized that AAV
mediated delivery of XIAP should provide neuroprotection in
these progressive retinal degenerations given its efficacy in acute
insult. The data show that XIAP is able to significantly protect
photoreceptors at both the structural and functional level in the
P23H model of RP, and protects photoreceptor structure in the
S334ter model. Therefore, XIAP gene therapy is of potential use
in the treatment of human RP.
RESULTS
Homozygous albino P23H and S334ter transgenic animals were
crossed onto a pigmented Long Evans background to yield
heterozygous pigmented offspring. These crosses were conducted
because assessment of neuroprotection in a pigmented eye would
more closely resemble the gene therapy situation in humans. Based
on electroretinography, the retinal degeneration for these
pigmented animals appeared to be unaffected in the S334ter
animals, but was somewhat delayed in the P23H animals
(Fig. 1A,B), perhaps due to increased phototoxicity for this
mutation on the albino background [34]. In order to assess XIAP
neuroprotection of photoreceptors in the retinas of pigmented
P23H and S334ter animals, rats were given a subretinal injection
of hemagglutinin (HA)-tagged AAV-XIAP or AAV-GFP at
postnatal day 14–17, when the eyelids opened. Serotype 5 AAV
was used to ensure rapid upregulation of the transgene in
photoreceptors.
XIAP Overexpression in the Retina correlates with
Structural Protection of Photoreceptor Cells
To assess structural neuroprotection, histology was conducted on
eyes sampled at 28 weeks after AAV injection. XIAP treatment
preserved outer nuclear layer (ONL) morphology in both P23H
and S334ter animals. XIAP-treated retinas possessed multiple
layers of photoreceptors (Fig. 2A), and were significantly thicker
(Fig. 2B) than their contralateral untreated counterparts as well as
similarly age-matched GFP-treated controls.
Western blotting confirmed that the HA-tagged XIAP protein
was overexpressed in the retinas of injected eyes and undetectable
in the contralateral control eyes (Fig. 3A). Furthermore, immuno-
histochemistry confirmed XIAP overexpression at sites of
photoreceptor preservation (Fig 3B). Using an anti-HA antibody,
the tagged XIAP transgene was clearly seen in photoreceptor
inner and outer segments and coincided perfectly with preserved
ONL morphology. Sections were counterstained with a DAPI
nuclear stain in order to emphasize ONL structure and thickness.
Moving away from the site of AAV injection, XIAP immunoflu-
orescence was found to diminish, as was ONL thickness. As
expected, the retina of the uninjected contralateral eye showed no
HA immunofluorescence and possessed a uniformly diminished
ONL (Fig. 3C).
Figure 1. Photoreceptor degeneration is slowed in P23H animals crossed onto the Long Evans (LE) pigmented background in comparison to albino
transgenic animals (A), but not in S334ter animals (B). B-wave data (+/- SEM) was taken from the contralateral untreated eyes of experimental animals.
N=5 for all groups.
doi:10.1371/journal.pone.0000314.g001
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photoreceptor inner segments of AAV-GFP injected eyes. Retinal
sections showing the border between GFP expressing cells and
cells not covered by the virus conclusively demonstrated that the
thickness of the ONL is unaffected by the presence of AAV-GFP
(Fig. 3D).
Functional Protection of Photoreceptor Cells
Electroretinography was conducted to assess the effects of XIAP
gene therapy on retinal function. Electroretinograms (ERGs)
record the combined electrical activity of the various components
of the retina following flashes of light, and can be divided into
a hyperpolarizing a-wave and a depolarizing b-wave. While the b-
wave is accepted as a reliable measure of overall retinal function,
the a-wave is generated more specifically by the photoreceptor
cells. Ratios of the a- and b-wave amplitude in the treated eye to
that in the untreated eye were used to assess preservation of visual
function following gene therapy.
For the S334ter animals, no preservation of the a-wave was
identified at any of the timepoints (Fig. 4A). The b-wave amplitude
ratios for XIAP treated eyes appeared to be somewhat, although
not significantly, better than the GFP control ratios up to
Figure 2. Structural protection of photoreceptors. A) Haematoxylin and Eosin staining of retinal sections at 28 weeks after AAV subretinal injection.
XIAP-treated retinas have increased layers of photoreceptor nuclei in comparison to contralateral untreated controls as well as age-matched GFP-
treated controls. B) For the LE-P23H animals, XIAP-treatment preserves the ONL in comparison to both the untreated control eyes (p,0.0001) and
GFP-treated eyes (p,0.0001) (XIAP N=16, GFP N=4). For LE-S334ter, XIAP-treated eyes are similarly significantly better than untreated controls
(p,0.001) and GFP-treated eyes (p,0.005) (XIAP N=15, GFP N=8).
doi:10.1371/journal.pone.0000314.g002
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performance in the XIAP group declined and was comparable to
the GFP control group. Overall, there was no lasting or significant
functional protection resulting from XIAP treatment in the
S334ter animals.
For the P23H animals, there was a clear difference between the
a-wave and b-wave amplitude ratios for the XIAP treated group in
comparison to the GFP treated group across all timepoints
(Fig. 4C, D). These differences appeared to increase with time, as
the degeneration progressed in the contralateral untreated eye. A
repeated measures ANOVA with Bonferroni-Dunn correction
revealed a significant difference between the XIAP and GFP
treated groups for both the a-wave (p,0.001) and b-wave
amplitudes (P,0.03).
DISCUSSION
A comprehensive gene therapy approach which would target
retinal degeneration must be widely applicable given the number
of different mutations which can cause retinal disease. In RP
alone, more than 39 different genetic loci have been discovered
and the causative gene has only been identified in 28 of these [4].
Given all the different mutations in all the different genes, gene
therapy for RP would be a daunting task if one attempted to target
all possible mutations. A final common pathway for all the types of
RP is cell death by apoptosis. Thus, targeting and preventing the
apoptotic event may represent a general and pragmatic approach
to the treatment of a wide variety of mutations leading to disease.
There is controversy in the literature on the mechanism of
apoptotic death in retinal degeneration with regards to the
presence [35,36,37] or absence [38] of caspase activation. The
success of our gene therapy in the two animal models presented in
this study suggests that caspases are involved, since XIAP binds to
and inhibits the action of caspases 3, 7 and 9. Our results show
great promise for XIAP gene therapy in the treatment of RP. We
show strong preservation of ONL morphology coincident with
XIAP over-expression in both P23H and S334ter rats, while non-
injected controls and AAV-GFP-treated animals undergo pro-
gressive degeneration. ERG data reveal significant differences in
retinal function in the eyes of XIAP-treated P23H animals in
comparison to those treated with GFP for both a-wave and b-wave
measures. These differences are not as pronounced in the early
stages of disease progression as would be predicted based on the
loss of photoreceptors, most likely due to some level of redundancy
in the retinal circuitry. However, ERG differences between XIAP
and control groups appear to increase with time, undoubtedly due
to the continuing retinal degeneration in the control eyes. The
finding of a greater preservation of a-wave amplitude in
comparison to b-wave (indicated by larger amplitude ratios when
comparing treated to untreated eyes) is expected. This is based on
the fact that the a-wave is generated primarily by the
photoreceptors, which were the targets of the gene therapy,
whereas the b-wave is indicative of overall retinal function.
While significant differences in the ERG amplitude are evident
between XIAP and GFP-treated P23H animals, several factors
likely masked the true magnitude of the protective effect. These
variables also explain why the amplitude ratios were slightly below
1 at the earlier timepoints, even for the XIAP-treated group. The
trans-corneal subretinal injection procedure may cause some
damage to the eye that might impede ERG recordings. The nature
of this damage could be wide-ranging. The procedure causes
a localized detachment of the retina, which eventually resolves but
may leave some residual damage. The injection often causes some
bleeding of pigment into the corneal scar, that in a few occasions
can lead to completely ‘bound’ pupils (synechiae) which have lost
Figure 3. A) Western blot confirmation of XIAP over-expression in
injected eyes in P23H animals in comparison to the contralateral control
uninjected eye in the same animal. Blot was probed with an anti-HA
antibody. Given that the protein extracts were made from the whole
retina, and only a fraction of the retina was covered by the subretinal
injection, XIAP protein levels seen on the Western blot are an under-
estimation of the level of over-expression at the site of injection. Some
variability in XIAP expression is present between animals. Ponceau red
staining of membrane confirms equal loading. (B) Anti-HA immunoflu-
orescence (green) confirms XIAP over-expression at site of neuropro-
tection in a P23H animal. (C) Contralateral untreated control has no
fluorescence and shows diminished ONL thickness. (D) GFP-injected
retina of a S334ter animal is shown at boundary between photo-
receptors covered by the virus and photoreceptors outside the range of
the virus. ONL thickness is similar on either side of the virus boundary.
Sections are counterstained with DAPI (nuclear stain).
doi:10.1371/journal.pone.0000314.g003
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been estimated to cause cataracts in 20–40% of animals [39] . All
of these abnormalities can obstruct the transmission of the ERG
light stimulus into the eye. In this study, animals with completely
bound pupils or large cataracts were removed from the study, but
those with corneal bleeds or minor cataracts remained, possibly
reducing the amplitude of the ERG response in the treated eyes in
comparison to the contralateral untreated eyes. An additional
factor which may have masked the magnitude of the protective
effect is the fact that a single subretinal injection covers
approximately 20% of the retina [40], but the ERG records the
response from the whole retina. Thus, the full extent of functional
protection at the site of injection could be masked by the response
of the majority of the retina which was not covered by the virus
and continued to degenerate. Many of these limitations would not
be relevant to the treatment of human disease which would involve
much more sophisticated surgical procedures, viral delivery and
multi-focal ERG assessment.
The completely different nature of the mutations in the two
transgenic lines may offer an explanation for the presence of long-
term functional protection in P23H animals and the clear absence
of such protection in the S334ter line. Rhodopsin mutations have
been divided into several classes based predominantly on their
behavior in tissue culture experiments [41,42]. S334ter represents
a Class I mutant, while P23H is a member of the more
predominant Class II mutations. Class I mutants have impaired
trafficking to the rod outer segment, where phototransduction
occurs. The S334ter mutant protein accumulates to high levels in
the plasma membrane, where it may interfere with synaptic
transmission, or the transport of cellular cargo [11,12]. Class II
mutants such as P23H are thought to be defective in protein
folding, and prone to aggregation (reviewed in [41,42]). P23H
mutant protein becomes multi-ubiquitinylated, and accumulates in
cytoplasmic aggresomes; this destabilizes the protein and targets it
for degradation via the ubiquitin proteosome system [43,44]. The
precise mechanisms by which these mutations lead to apoptotic
cell death remains unknown, but they clearly have very different
effects on the transport and function of rhodopsin.
The P23H results are more relevant for the treatment of human
disease, since this same mutation is causative in approximately
12% of human adRP cases in North America [10]. Since P23H
also represents the larger group of class II rhodopsin mutations,
XIAP gene therapy may be equally effective in protecting against
other RP-causing misfolding rhodopsin mutations. Even if XIAP
Figure 4. To assess functional preservation, the a- or b-wave amplitude of the treated eye was divided by that of the contralateral, untreated eye to
give an amplitude ratio. Amplitude ratios from the 8
th luminance step (0.63 cd.s/m
2) are graphed. Amplitude ratios for LE-S334ter animals (A,B) show
no significant differences between treated and control retinas. Ratios for LE-P23H animals (C,D) show significant differences for a-wave (p,0.001) and
b-wave (p,0.03) by ANOVA. For statistical analyses, N values were 12 and 3 for XIAP and GFP respectively.
doi:10.1371/journal.pone.0000314.g004
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the rod photoreceptors, this may still have significant effects on
visual outcome in humans. In RP, the initial phase of mutant rod
cell loss is followed by a wave of cone cell death [45–48]. The
underlying mechanisms of these secondary effects are not known,
but it may be that apoptosis of the rods causes changes in chemical
or mechanical forces on the surviving cones, resulting from the
release of toxic factors into the retina or the loss of structural
support. By preventing rod structural loss, XIAP may still help to
retain cone structure and function (i.e. day and colour vision). This
would be very important in humans, who have a cone-dominant
central retina.
Previous gene therapy studies for the treatment of retinal
degenerations have targeted the apoptotic response. These studies
have examined the therapeutic potential of over-expression of the
bcl-2 family of proteins through viral delivery or transgenesis, but
the success of these studies has been limited. Bcl-2 is able to delay
photoreceptor degeneration in various murine disease models, but
the protective effects are transient, persisting for only 4 to 6 weeks
before regressing to the untreated levels [49–51]. Moreover, high
levels of bcl-2 over-expression in photoreceptors promote retinal
degeneration rather than preventing it, and so gene dosage is
critical [50]. In addition, neuron specific enolase (NSE)-driven bcl-
2 over-expression prevents the naturally occurring apoptotic
mechanisms required during normal development [52]. In our
experience, increasing levels of XIAP have not had any deleterious
effects on photoreceptors. Furthermore, XIAP transgenic animals,
where the transgene is driven by the NSE promoter, undergo
normal developmental apoptosis [27].
These results clearly demonstrate the potential of XIAP gene
therapy for the treatment of inherited retinal degenerations. It is
important to note that the XIAP treatment does not represent an all-
encompassing gene therapy strategy for retinal degeneration. Some
forms of retinal disease may be associated with developmental,
structural or RPE defects. In these cases, preventing cell death of
photoreceptors will not repair the damage and will not induce vision
where none exists. However, many retinal degenerations are
associated with normal vision and development early in life and
are later triggered by some, as yet unknown, mechanism which
results in photoreceptor death by apoptosis. Thus, targeting
apoptosis through XIAP gene therapy may yield a general and
widely applicable approach for these types of retinal disease.
MATERIALS AND METHODS
Animals
Line 1 P23H and line 4 S334ter transgenic rats were generously
donated by Dr. Matt LaVail (UCSF, CA). Homozygous transgenic
animals were crossed with wild-type Long Evans rats (Charles
River Laboratories, Wilmington, MA), to generate transgenic
pigmented offspring. Animals were reared under standard
laboratory conditions in accordance with the Association of
Research in Vision and Ophthalmology (ARVO) Statement for
the Use of Animals in Ophthalmic and Vision Research and the
guidelines of the University of Ottawa Animal Care and
Veterinary Service.
Construction of rAAV Vectors
A cDNA construct encoding the full-length human XIAP open
reading frame with an N-terminal hemagglutinin (HA) tag was
inserted into a pTR vector under the control of the chicken b-actin
promoter. A GFP construct was generated in a similar manner for
use as a negative control. A woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) was placed in the 39
untranslated region of the construct to enhance expression of the
viral transgene. Serotype 5 rAAV was generated as previously
described [53,54]. The viral titers were adjusted to 4.0610
13
physical particles/ml for AAV-GFP, and 3.0610
14 physical
particles/ml for AAV-XIAP. Ratios of physical to infectious
particles were lower than 100. The rAAV vectors, purified using
iodixanol gradient/heparin-affinity chromatography, were more
than 99% pure, as judged by polyacrylamide silver-stained gel
electrophoresis (data not shown). Contaminating helper adenovi-
rus and wild-type AAV, assayed by serial dilution cytopathic effect
or infectious center assay respectively, were below detection levels.
Subretinal Injections
Subretinal injections were done within 3 days of the opening of the
eyes, between post-natal day 14 (P14) and P17. Injections were
conducted under isofluorane anesthesia, as previously described
[33,55]. A 2-ul volume of virus (rAAV-XIAP or rAAV-GFP), diluted
50:1 with fluorescein tracer was injected into the sub-retinal space of
the eye, in the central retina, nasal to the optic disc. The fluorescein
tracer allowed immediate visualization and evaluation of the
injection location. The sub-retinal injection procedure caused
a localized retinal detachment which has been previously shown to
resolve within several days post surgery [55]. For the S334terstudies,
20 animals received rAAV-XIAP and 10 animals received rAAV-
GFP. Two animals were eliminated from each group due to
cataracts or complete synechiae, resulting in final numbers of 18 for
rAAV-XIAP and 8 for rAAV-GFP. For the P23H studies, 20
animals were injected with rAAV-XIAP and 7 received rAAV-GFP.
Two animals were eliminated from the first group and 3 from the
second, resulting in 18 animals for rAAV-XIAP and 4 animals for
rAAV-GFP. The injected eye was alternated between right and left,
to eliminate any potential bias due to slight differences in the corneal
surface electrodes used for ERG recordings.
Electroretinography
Full-field scotopic/photopic electroretinograms were generated
using the ESPION system (Diagnosys LLC, Littleton, MA). Rats
were weighed and dark-adapted overnight prior to ERG analysis.
Under safe-light conditions, the animals were anaesthetized with
an intraperitoneal injection of 30mg/kg ketamine hydrochloride
(Bimeda-MTC, Cambridge, ON) and 0.5 mg/kg medetomidine
hydrochloride (Domitor, Novartis, Finland). After 1 hour under
anaesthesia, the medetomidine was reversed using 1 mg/kg of
atipamezole hydrochloride (Antisedan, Novartis, Finland). Eyes
were dilated using both 1% tropicamide and 2.5% phenylephrine
hydrochloride (Alcon Canada), applied at 20 and 5 minutes prior
to the test, in order to ensure complete dilation. During testing,
animals were placed on a water circulating heating pad (Gaymar
T/Pump, Orchard Park, NY) to maintain a constant body
temperature throughout the test.
Silver wire loop electrodes were placed on both corneas with
a drop of 0.3% hypromellose (Novartis) to maintain corneal
hydration. A gold minidisc reference electrode was placed on the
tongue and a ground needle electrode was placed subcutaneously
in the tail. The animal’s head was positioned under the center of
the Ganzfeld dome. Single flash stimuli (4 ms duration) were
presented at eleven increasing intensities ranging from 0.001 cd.s/
m
2 to 25 cd.s/m
2. Five ERG traces were obtained and averaged
for each luminance step. ERGs were recorded for all animals at
biweekly timepoints, commencing two weeks after the subretinal
injection procedure, and continuing up to 28 weeks post-injection.
The analyses of ERG data presented here were conducted on the
8
th luminance step (0.63 cd.s/m
2) of the 11 step series.
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Western blots were generated with protein extracts from XIAP
injected eyes and contralateral uninjected control eyes. Eyes were
enucleated and retinas isolated two weeks after the subretinal
injection. Each retina was sonicated in 200 mL RIPA buffer
(50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1%
NP-40, 0.25% Na-deoxycholate, 1mMNaF, 1mMNa3VO4,1m M
phenylmethylsulfonyl fluoride [PMSF], and 10 mg/mL each of
leupeptin and aprotinin). The samples were rocked at 4uC for 1
hour, and then centrifuged in an IEC microfuge for 15 minutes at
4uC and 13000 RPM. Protein concentration was determined using
the DC protein assay (Bio-Rad). Twenty micrograms of protein
from each eye was electrophoresed on a 12% sodium dodecyl
sulfate-polyacrylamide (SDS-PAGE) gel, and transferred onto
a polyvinylidene fluoride (PVDF) membrane (Immobilon P,
Millipore). Blots were probed with an antibody to the HA epitope
tag (1: 2,500 Rat anti-HA, Roche Molecular Biochemicals),
followed by an anti-Rat horseradish peroxidase secondary antibody
(1 in 20,000, Amersham Pharmacia). Protein detection was
achieved using a SuperSignal West Pico Chemiluminescent Sub-
strate detection kit (Pierce Biotechnology, Rockford, IL).
Tissue Fixation and Processing
Eyes were sampled at 28 weeks post-injection, (at approx.
30 weeks of age in the animal), when the degeneration in the
untreated, control eye was extensive. Tissue sampling was
conducted as previously described [25]. Tissue sections (12–
15 mm) were cut using a Shandon cryostat, air dried for 2 hours,
and stored at 220uC with dessicant. Haematoxylin & Eosin (H &
E) staining was done according to standard protocols.
Measurements of ONL thickness were taken near the site of the
injection in the treated animals and at the same distance from the
optic nerve head in the contralateral untreated eyes. Images were
obtained at 406magnification using a Zeiss Axioskop microscope
with an AxioCam Hrc camera. ONL thickness was measured in
five evenly spaced sections near the injection site for each retinal
image, averaged and compared between treated eyes and their
contralateral, untreated counterparts.
Immunohistochemistry
Immunohistochemistry was used to localize the HA tagged XIAP
transgene. Sections were probed with a rat anti-HA primary
antibody (1:500, Roche Molecular Biochemicals) followed a goat
anti-rat IgG secondary antibody (Alexafluor 488, 1:400, Molecular
Probes). Slides were counterstained with the nuclear stain 49,6 9-
diamindino-2-phenylindole dihydrochloride (DAPI; 1:10000,
D9542, Sigma-Aldrich). GFP fluorescence was readily observable
under fluorescence filters on the microscope after re-hydration of
retinal sections. Images were obtained using a Zeiss Axioskop light
microscope with a Zeiss AxioCam HRc camera.
Statistical Analysis
For assessment of ONL thickness, a 1-tailed paired t-test was used
for comparisons between injected and uninjected eyes within the
same animal, while a 1-tailed independent samples t-test was used
to detect differences between the XIAP treated eyes and GFP
injected control eyes in different groups of animals.
For ERG analyses, a repeated measures ANOVA with
a Bonferroni-Dunn correction for multiple comparisons was used
to detect a difference between XIAP and GFP treated groups.
ANOVA requires equal numbers of data points at all timepoints;
thus only animals which had ERG recordings every two weeks and
were present in the study until 28 weeks post-injection were used
for these analyses. Animals that lacked ERG data at any timepoint
because of difficulties with plane of anesthesia were not included in
the analysis. All statistics were done using StatView Version 4.57
(Abacus Concepts, Berkeley, CA, USA).
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